Nvidia's AI Startup Deal, Soaring Mining Stocks, and Tesla's Safety Probe | Stock Movers

Nvidia's Strategic AI Deal

• 💡 Nvidia (NVDA) is up after agreeing to a licensing deal with AI startup Groq.
• 🚀 The agreement grants Nvidia the right to use Groq's technology and integrate its chip design into future products.
• 🧠 Some Groq executives are joining Nvidia to support this initiative, while Groq will continue as an independent company.
• 📈 Analysts view the move as strategic, leveraging Nvidia's balance sheet to maintain dominance and enhance its full-system stack.
• 📊 Nvidia shares are up 42% year-to-date.

Mining Stocks Surge on Record Metal Prices

• 📈 Mining companies like Coeur (CDE) and Freeport (FCX) are experiencing significant gains.
• 🌟 This surge is driven by record highs in gold, silver, and platinum, and a rally in copper prices.
• 💰 Analysts are bullish on copper mining stocks, citing supply constraints and growing global demand, with expectations for continued strong performance.
• 🚀 Coeur shares are up an impressive 233% year-to-date.

Tesla Faces Scrutiny Over Emergency Door Releases

• ⚠️ Tesla (TSLA) shares have fallen amid renewed scrutiny from US auto safety regulators.
• 🔍 The National Highway Traffic Safety Administration (NHTSA) has opened a probe into the emergency releases in certain Model 3 vehicles.
• ❓ Regulators are evaluating claims that the mechanical door release is difficult to locate during an emergency, potentially posing a danger.
• 🗣️ The probe stems from a petition filed by a Tesla owner who reported being trapped in his vehicle.
• ⚖️ NHTSA has not yet decided whether to grant or deny the petition.

Biohaven's Disappointing Drug Trial Results

• 📉 Biohaven (BHVN) shares experienced a significant drop earlier in the session after a mid-stage study for its experimental drug BHV-7,000 for major depressive disorder missed its primary endpoint.
• 😔 Analysts described the data as disappointing, but investor focus has shifted to upcoming late-stage epilepsy study data, which may have mitigated the impact of the missed endpoint.
• 🗓️ The company does not plan additional psychiatric clinical trials until 2026.